{"id":11320,"date":"2024-08-14T13:41:05","date_gmt":"2024-08-14T13:41:05","guid":{"rendered":"https:\/\/www.friendly-bartik.94-130-216-58.plesk.page\/studien\/"},"modified":"2026-06-15T12:34:41","modified_gmt":"2026-06-15T12:34:41","slug":"studien","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/studien\/","title":{"rendered":"Studien"},"content":{"rendered":"\n
\n
\n
RESEARCH & PROJECTS<\/h5>

SCIENCE & PROJECTS<\/strong><\/h1>\n <\/div>\n <\/div>\n\n\n\n
<\/div>\n\n\n\n

AFNET plans and conducts investigator-initiated studies, registries and research projects. Below you will find an overview of the current studies with AFNET as sponsor:<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n \n
2030<\/div>\n
2029<\/div>\n
2028<\/div>\n
2027<\/div>\n
2026<\/div>\n
2025<\/div>\n
2024<\/div>\n
2023<\/div>\n
2022<\/div>\n
2021<\/div>\n
2020<\/div>\n
2019<\/div>\n
2018<\/div>\n
2017<\/div>\n
2016<\/div>\n
2015<\/div>\n
2014<\/div>\n
2013<\/div>\n
2012<\/div>\n
2011<\/div>\n
2010<\/div>\n
2009<\/div>\n
2008<\/div>\n
2007<\/div>\n
2006<\/div>\n
2005<\/div>\n
2004<\/div>\n
2003<\/div>\n <\/div>\n\n\n\n\n
\n
\n
\n

2021 \u2013 bis ca. 2026.<\/p>\n

MAESTRIA – AFNET 10<\/strong><\/p>\n

Machine Learning\u00a0Artificial Intelligence\u00a0Early Detection\u00a0STroke Atrial Fibrillation.<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n

\n
\n
\n

2021 \u2013 bis ca. 2022<\/p>\n

Smart in OAC-AFNET 9 <\/strong> <\/p>\n

Die vollst\u00e4ndig ferngesteuerte, vom Pr\u00fcfer initiierte Smartphone- und Wearable-Erkennung von Vorhofarrhythmien bei \u00e4lteren Erwachsenen<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n\n

\n
\n
\n

2017 \u2013 bis ca. 2022<\/p>\n

AXADIA<\/strong><\/p>\n

Eine Sicherheitsstudie zur Bewertung der oralen Antikoagulation mit Apixaban im Vergleich zu Vitamin-K-Antagonisten bei Patienten mit Vorhofflimmern (AF) und Nierenerkrankungen im Endstadium (ESKD) unter chronischer H\u00e4modialysebehandlung<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n

\n
\n
\n

2016 \u2013 bis ca. 2022<\/p>\n

NOAH- AFNET 6 <\/strong> <\/p>\n

Nicht-Vitamin K-abh\u00e4ngige orale Antikoagulanzien bei Patienten mit atrialen Hochfrequenzepisoden.<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n
\n

2011 \u2013 bis ca. 2020<\/p>\n

EAST \u2013 AFNET 4 <\/strong> <\/p>\n

Early treatment of\u00a0atrial fibrillation for\u00a0stroke prevention\u00a0trial (EAST)<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n

\n
\n
\n

2015 \u2013 bis ca. 2017<\/p>\n

AXAFA \u2013 AFNET 5<\/strong><\/p>\n

Antikoagulation mit dem direkten Faktor-Xa-Inhibitor Apixaban w\u00e4hrend der Katheterablation von Vorhofflimmern: Vergleich zur Therapie mit Vitamin-K-Antagonisten (AXAFA)<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n \n\n\n\n\n\n \n\n\n\n

\n
\n
\n

Studiendauer: ca. 6 Jahre <\/p>\n

EASThigh \u2013 AFNET 11 <\/strong> <\/p>\n

The Early atrial fibrillation Ablation for STroke prevention in patients with high comorbidity burden\u00a0<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n \n

\n
\n
\n

2006 \u2013 bis ca. 2010<\/p>\n

Gap-AF \u2013 AFNET 1 Studie <\/strong><\/p>\n

Eine randomisierte Studie zur Untersuchung der Bedeutung der vollst\u00e4ndigen gegen\u00fcber der unvollst\u00e4ndigen elektrischen Isolierung von Lungenvenen durch Radiofrequenz-induzierte lineare L\u00e4sionen.<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n\n

\n
\n
\n

2005 \u2013 bis ca. 2011<\/p>\n

Flec-SL \u2013 AFNET 3 Studie <\/strong><\/p>\n

Antiarrhythmika Therapie nach Kardioversion.<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n

\n
\n\n
\n

2005 \u2013 bis ca. 2009<\/p>\n

ANTIPAF \u2013 AFNET 2 Studie<\/strong><\/p>\n

Angiotensin II-Antagonist bei paroxysmalem Vorhofflimmern Studie<\/p>\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n

<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n